Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

被引:497
作者
Cho, Jang Hwan [1 ,2 ]
Collins, James J. [3 ,4 ,5 ,6 ,7 ,8 ]
Wong, Wilson W. [1 ,2 ]
机构
[1] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
[2] Boston Univ, Biol Design Ctr, Boston, MA 02215 USA
[3] MIT, Synthet Biol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[4] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[5] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[6] Harvard MIT Program Hlth Sci & Technol, Cambridge, MA 02139 USA
[7] Broad Inst MIT & Harvard, 415 Main St, Cambridge, MA 02142 USA
[8] Harvard Univ, Wyss Inst Biol Inspired Engn, 3 Blackfan Circle, Boston, MA 02115 USA
基金
美国国家科学基金会; 英国生物技术与生命科学研究理事会;
关键词
B-CELL; OVARIAN-CANCER; FUSION PROTEINS; TARGET-CELLS; HALF-LIFE; IN-VITRO; CAR; INTRAPERITONEAL; STIMULATION; RECOGNITION;
D O I
10.1016/j.cell.2018.03.038
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here, we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical "upgrades," such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system.
引用
收藏
页码:1426 / +
页数:24
相关论文
共 65 条
  • [1] Toxicity and management in CAR T-cell therapy
    Bonifant, Challice L.
    Jackson, Hollie J.
    Brentjens, Renier J.
    Curran, Kevin J.
    [J]. MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 : 16011
  • [2] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
    Brentjens, Renier J.
    Davila, Marco L.
    Riviere, Isabelle
    Park, Jae
    Wang, Xiuyan
    Cowell, Lindsay G.
    Bartido, Shirley
    Stefanski, Jolanta
    Taylor, Clare
    Olszewska, Malgorzata
    Borquez-Ojeda, Oriana
    Qu, Jinrong
    Wasielewska, Teresa
    He, Qing
    Bernal, Yvette
    Rijo, Ivelise V.
    Hedvat, Cyrus
    Kobos, Rachel
    Curran, Kevin
    Steinherz, Peter
    Jurcic, Joseph
    Rosenblat, Todd
    Maslak, Peter
    Frattini, Mark
    Sadelain, Michel
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)
  • [3] Toxicities of chimeric antigen receptor T cells: recognition and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 127 (26) : 3321 - 3330
  • [4] Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
    Cartellieri, M.
    Feldmann, A.
    Koristka, S.
    Arndt, C.
    Loff, S.
    Ehninger, A.
    von Bonin, M.
    Bejestani, E. P.
    Ehninger, G.
    Bachmann, M. P.
    [J]. BLOOD CANCER JOURNAL, 2016, 6 : e458 - e458
  • [5] Improving the efficacy of antibody-based cancer therapies
    Carter, P
    [J]. NATURE REVIEWS CANCER, 2001, 1 (02) : 118 - 129
  • [6] Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
    Caruso, Hillary G.
    Hurton, Lenka V.
    Najjar, Amer
    Rushworth, David
    Ang, Sonny
    Olivares, Simon
    Mi, Tiejuan
    Switzer, Kirsten
    Singh, Harjeet
    Huls, Helen
    Lee, Dean A.
    Heimberger, Amy B.
    Champlin, Richard E.
    Cooper, Laurence J. N.
    [J]. CANCER RESEARCH, 2015, 75 (17) : 3505 - 3518
  • [7] Molecular mechanisms of T cell co-stimulation and co-inhibition
    Chen, Lieping
    Flies, Dallas B.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2013, 13 (04) : 227 - 242
  • [8] T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
    Chmielewski, M
    Hombach, A
    Heuser, C
    Adams, GP
    Abken, H
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (12) : 7647 - 7653
  • [9] Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
    Davila, Marco L.
    Riviere, Isabelle
    Wang, Xiuyan
    Bartido, Shirley
    Park, Jae
    Curran, Kevin
    Chung, Stephen S.
    Stefanski, Jolanta
    Borquez-Ojeda, Oriana
    Olszewska, Malgorzata
    Qu, Jinrong
    Wasielewska, Teresa
    He, Qing
    Fink, Mitsu
    Shinglot, Himaly
    Youssif, Maher
    Satter, Mark
    Wang, Yongzeng
    Hosey, James
    Quintanilla, Hilda
    Halton, Elizabeth
    Bernal, Yvette
    Bouhassira, Diana C. G.
    Arcila, Maria E.
    Gonen, Mithat
    Roboz, Gail J.
    Maslak, Peter
    Douer, Dan
    Frattini, Mark G.
    Giralt, Sergio
    Sadelain, Michel
    Brentjens, Renier
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
  • [10] Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
    Di Stasi, Antonio
    Tey, Siok-Keen
    Dotti, Gianpietro
    Fujita, Yuriko
    Kennedy-Nasser, Alana
    Martinez, Caridad
    Straathof, Karin
    Liu, Enli
    Durett, April G.
    Grilley, Bambi
    Liu, Hao
    Cruz, Conrad R.
    Savoldo, Barbara
    Gee, Adrian P.
    Schindler, John
    Krance, Robert A.
    Heslop, Helen E.
    Spencer, David M.
    Rooney, Cliona M.
    Brenner, Malcolm K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) : 1673 - 1683